Dino Mustafić

February 19, 2020 Off

Mereo BioPharma gets investment of $3 Million

Mereo BioPharma has entered into a Securities Purchase Agreement with a new U.S.-based institutional healthcare investor. Under the terms of the Agreement, the institutional investor has agreed to make an investment of $3 million to purchase 12,252,715 of the Company’s ordinary shares (equivalent to 2,450,543 American Depository shares (ADSs)) at a price equivalent to 18.8 pence per share, which represents a 20% discount over Mereo’s closing share price of 23.5 pence on AIM on February 18, 2020.

February 10, 2020 Off

Arctoris, Molecule to tackle the innovation crisis in drug discovery and development

By Dino Mustafić

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug…

February 10, 2020 Off

Stevanato Group partners with Pfeiffer Vacuum to deliver effective biopharma industry testing

By Dino Mustafić

Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for combination products, has announced an agreement with Pfeiffer Vacuum Technologies to provide characterization testing of container-closure systems for the biopharma industry.

January 28, 2020 Off

Adverum Biotechnologies opens new HQ in Redwood City, San Francisco

By Dino Mustafić

Clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, Adverum Biotechnologies on Tuesday announced the opening of its new corporate headquarters at one of the largest biotechnology research complexes in the San Francisco Bay Area.

January 27, 2020 Off

Affiris to proceed with P2study with lead treatment for Parkinson’s

By Dino Mustafić

AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.

December 20, 2019 Off

Hutschison China MediTech get’s priority review status for its anti-cancer drug surufatinib

By Dino Mustafić

Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).

December 17, 2019 Off

Symbiosis invests £1.5m in Stirling site

By Dino Mustafić

#Symbiosis Pharmaceutical Services has invested over £1.5m ($1.9m) during the last year, to expand its sterile biologics manufacturing facility in Scotland, UK by 25%.

December 17, 2019 Off

Roche buys Spark Therapeutics for $4.3 billion

By Dino Mustafić

Swiss-based Roche’s is buying Spark Therapeutics for of $114.50 per share in cash, total $4.3 billion through its fully owned subsidiary 022019 Merger Subsidiary.

December 12, 2019 Off

Inceptua names new CEO, adds to board of directors

By Dino Mustafić

Inceptua, a pharmaceutical company and service partner in comparator sourcing for clinical trials, through early access programs to licensing and commercialization of products, said Wednesday that Stefan Fraenkel, Executive Vice President, and Member of the Executive Leadership Team, is promoted to CEO effective 1 January, 2020.

December 11, 2019 Off

The power of collaboration: tackling pharmaceutical challenges

By Dino Mustafić

Pharmaceutical companies have started to embrace a more collaborative way of working as part of a movement to help overcome some of the challenges the industry is facing. Expiring patents and a tight regulatory environment are just some of the issues that are hoped to be resolved through forming partnerships across the industry, and even with competitors.